Overview

Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The study will test the tolerability and efficacy of the combination therapy Imatinib/Hydroxyurea (HU) in patients with chronic myeloid leukemia (CML) in first chronic phase (CP1) newly diagnosted or failing interferon-based therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Leipzig
Treatments:
Hydroxyurea
Imatinib Mesylate